- CFD trading
- CFD trading
- Markets
- Markets
- Products overview
- Forex
- Commodities
- Metals
- Indices
- Shares
- Cryptocurrencies
- Treasuries
- ETFs
- Accounts
- Accounts
- Compare our accounts
- Our spreads
- Funding & withdrawals
- Open CFD account
- Try free demo
- Platforms
- Platforms
- Platforms overview
- GO Markets trading app
- MetaTrader 4
- MetaTrader 5
- cTrader
- cTrader copy trading
- Mobile trading platforms
- GO WebTrader
- Premium trading tools
- Premium trading tools
- Tools overview
- VPS
- Genesis
- Share trading
- Share trading
- Invest in shares
- Invest in shares
- Trade ASX shares and ETFs
- Share trading platform
- Log into share trading
- Open share trading account
- Help centre
- Downloads
- Downloads
- iOS app
- Education
- Education
- Resources
- Resources
- News & analysis
- Education hub
- Economic calendar
- Earnings announcements
- Help & support
- Help & support
- About
- About
- About GO Markets
- Our awards
- Sponsorships
- Client support
- Client support
- Contact us
- FAQs
- Quick support
- Holiday trading hours
- Maintenance schedule
- Fraud and scam awareness
- Legal documents
Open Account
CFD trading
Trade CFDs on forex, commodities, indices, and more.
Open accountTo open a CFD trading account as a Company, Trust, or SMSF, apply here.
Share trading
Invest in shares and ETFs on the Australian share market.
Open accountOpen a Personal or Company/Trust/SMSF share trading account.
- CFD trading
- CFD trading
- Markets
- Markets
- Products overview
- Forex
- Commodities
- Metals
- Indices
- Shares
- Cryptocurrencies
- Treasuries
- ETFs
- Accounts
- Accounts
- Compare our accounts
- Our spreads
- Funding & withdrawals
- Open CFD account
- Try free demo
- Platforms
- Platforms
- Platforms overview
- GO Markets trading app
- MetaTrader 4
- MetaTrader 5
- cTrader
- cTrader copy trading
- Mobile trading platforms
- GO WebTrader
- Premium trading tools
- Premium trading tools
- Tools overview
- VPS
- Genesis
- Share trading
- Share trading
- Invest in shares
- Invest in shares
- Trade ASX shares and ETFs
- Share trading platform
- Log into share trading
- Open share trading account
- Help centre
- Downloads
- Downloads
- iOS app
- Education
- Education
- Resources
- Resources
- News & analysis
- Education hub
- Economic calendar
- Earnings announcements
- Help & support
- Help & support
- About
- About
- About GO Markets
- Our awards
- Sponsorships
- Client support
- Client support
- Contact us
- FAQs
- Quick support
- Holiday trading hours
- Maintenance schedule
- Fraud and scam awareness
- Legal documents
- Home
- News & analysis
- Shares and Indices
- Eli Lilly tops Wall Street expectations
- Founded: 1876
- Headquarters: Indianapolis, Indiana, United States
- Number of employees: 39,000 (2022)
- Industry: Pharmaceutical
- Key people: David A. Ricks (Chair, President, & CEO), Anat Ashkenazi (CFO)
- 5 day: +9.31%
- 1 month: +12.72%
- 3 months: +17.52%
- Year-to-date: +20.95%
- 1 year: +107.56%
- Cantor Fitzgerald: $630
- Wells Fargo & Company: $700
- Barclays: $680
- Morgan Stanley: $822
- Truist Financial: $650
- Deutsche Bank: $535
- Citigroup: $675
- UBS Group: $710
- Bank of America: $700
- Argus: $620
- Credit Suisse Group: $580
- BMO Capital Markets: $633
- The Goldman Sachs Group: $470
- Royal Bank of Canada: $580
- Volatility never sleeps. Trade over earnings releases as they happen outside of main trading hours
- Reduce your risk and hedge your existing positions ahead of a new trading day
- Extended trading hours on popular US stocks means extended opportunities
News & analysisEli Lilly and Company (NYSE: LLY) posted Q4 2023 earnings results before the opening bell on Wall Street on Tuesday.
The largest pharmaceutical company in the world reported revenue of $9.353 billion (up by 28% year-over-year) vs. $8.946 billion.
Earnings per share (EPS) also topped estimates at $2.49 vs. $2.296 per share. EPS grew by 19% vs. Q4 2022.
Eli Lilly expects to achieve revenue of between $40.4 billion and $41.6 billion in 2024. EPS expected to reach $12.20 to $12.70 per share.
Company overview
CEO commentary
“2023 was a year of tremendous achievement for Lilly, which delivered life-changing medicines to more patients than ever before resulting in strong revenue growth,” David A. Ricks, company CEO, said in a press release.
“We advanced our pipeline of new medicines for serious diseases and created new partnerships and innovative ways of collaborating to add to that pipeline. Lilly invested in the quality,
reliability and resilience of our supply chain with new advanced manufacturing plants and lines in the U.S. and in Europe. Entering 2024, we remain focused on the opportunity in front of us, to help solve some of the most challenging healthcare problems in the world and make life better for millions of patients,” Ricks added.Stock reaction
The stock initialy rose by around 5% from $705 to $742 at the market open on Tuesday, reaching a new all-time high.
Shares were flat at the end of trading, falling back down to $705.03 level.
Stock performance
Eli Lilly stock price targets
Eli Lilly and Company is the 9th largest company in the world with a market cap of $669.28 billion, according to CompaniesMarketCap.
You can trade Eli Lilly and Company (NYSE: LLY) and many other stocks from the NYSE, NASDAQ, HKEX and ASX with GO Markets as a Share CFD on the MetaTrader 5 platform. To find out more, go to “Trading” then select “Share CFDs”.
GO Markets offers pre-market and after-market trading on popular US Share CFDs.
Why trade during extended hours?
Sources: Eli Lilly and Company, TradingView, MarketWatch, MarketBeat, CompaniesMarketCap
Ready to start trading?
The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs. These documents are available here.
#Indice #Indices #IndicesTrading #IndexTrading #Shares #Stockmarket #StocksNext Article
Ford Q4 2023 results arrive above estimates – the stock is rising
Ford Motor Company (NYSE: F) released the latest financial results for Q4 of last year after the market closed on Tuesday. World’s 11th largest automaker did not disappoint investors and topped both revenue and earnings per share estimates (EPS). The company achieved revenue of $46 billion in the last 3 months of 2023 vs. $43.062 billion ex...
February 7, 2024Read More >Previous Article
FX analysis – AUD dips ahead of RBA, USD follows yields higher on Hawkish Powell, Gold hits 1-week lows
USD was bid in Mondays session with the US Dollar Index following US treasury yields higher after hawkish comments from Fed Chair Powell over the week...
February 6, 2024Read More >Please share your location to continue.
Check our help guide for more info.